1. Home
  2. SXTP
  3. SXTP News

Latest 60 Degrees Pharmaceuticals Inc. (SXTP) News on January 19, 2025

SXTP

Argus Research

2 days ago

Daily – Vickers Top Insider Picks for 01/17/2025

SXTP

Argus Research

3 days ago

Daily – Vickers Top Insider Picks for 01/16/2025

SXTP

Argus Research

4 days ago

Daily – Vickers Top Insider Picks for 01/15/2025

SXTP

Argus Research

5 days ago

Daily – Vickers Top Insider Picks for 01/14/2025

SXTP

Argus Research

6 days ago

Daily – Vickers Top Insider Picks for 01/13/2025

60 Degrees Pharmaceuticals enrolls first patient in tafenoquine study
SXTP

TipRanks

10 days ago

60 Degrees Pharmaceuticals enrolls first patient in tafenoquine study

SXTP

Argus Research

10 days ago

Daily – Vickers Top Insider Picks for 01/09/2025

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis
SXTP

GlobeNewswire

11 days ago

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

SXTP

Argus Research

11 days ago

Daily – Vickers Top Insider Picks for 01/08/2025

SXTP

Argus Research

12 days ago

Daily – Vickers Top Insider Picks for 01/07/2025

SXTP

Argus Research

13 days ago

Daily – Vickers Top Insider Picks for 01/06/2025

SXTP

Argus Research

16 days ago

Daily – Vickers Top Insider Picks for 01/03/2025

SXTP

Argus Research

19 days ago

Daily – Vickers Top Insider Picks for 12/31/2024

SXTP

Argus Research

20 days ago

Daily – Vickers Top Insider Picks for 12/30/2024

SXTP

Argus Research

23 days ago

Daily – Vickers Top Insider Picks for 12/27/2024

SXTP

Argus Research

24 days ago

Daily – Vickers Top Insider Picks for 12/26/2024

60 Degrees, Tufts Medical Center announces patent license agreement
SXTP

TipRanks

a month ago

60 Degrees, Tufts Medical Center announces patent license agreement

SXTP

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 12/24/2024

SXTP

MT Newswires

a month ago

60 Degrees Pharmaceuticals, Tufts Medical Center Sign Patent License Deal Over Potential Babesiosis Treatment

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention
SXTP

GlobeNewswire

a month ago

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

SXTP

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 12/23/2024

SXTP

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 12/20/2024

SXTP

Argus Research

a month ago

Daily – Vickers Top Insider Picks for 12/19/2024

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
SXTP

GlobeNewswire

a month ago

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
SXTP

ACCESSWIRE

2 months ago

VSee Health and 60 Degrees Pharmaceuticals Interviews Aired on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
SXTP

ACCESSWIRE

2 months ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates
SXTP

Zacks

2 months ago

60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
SXTP

GlobeNewswire

2 months ago

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
SXTP

GlobeNewswire

4 months ago

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

SXTP

MT Newswires

4 months ago

60 Degrees Pharmaceuticals Closes $4 Million Private Placement

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SXTP

GlobeNewswire

4 months ago

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
SXTP

GlobeNewswire

4 months ago

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
SXTP

GlobeNewswire

5 months ago

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations
SXTP

Simply Wall St.

5 months ago

60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations

60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates
SXTP

Zacks

5 months ago

60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
SXTP

GlobeNewswire

5 months ago

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Should You Add 60 Degrees Pharmaceuticals, Inc. (SXTP) to Your Stock Portfolio Right Now?
SXTP

Insider Monkey

5 months ago

Should You Add 60 Degrees Pharmaceuticals, Inc. (SXTP) to Your Stock Portfolio Right Now?

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
SXTP

GlobeNewswire

5 months ago

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
SXTP

GlobeNewswire

5 months ago

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support
SXTP

GlobeNewswire

6 months ago

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

60 Degrees Pharmaceuticals enters deals for babesiosis treatment trial
SXTP

Clinical Trials Arena

6 months ago

60 Degrees Pharmaceuticals enters deals for babesiosis treatment trial

SXTP

MT Newswires

6 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

SXTP

MT Newswires

6 months ago

Sector Update: Health Care

SXTP

MT Newswires

6 months ago

Top Midday Gainers

SXTP

MT Newswires

6 months ago

60 Degrees Signs Testing Deals for Potential Babesiosis Drug -- Shares Rise Pre-Bell

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
SXTP

GlobeNewswire

6 months ago

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
SXTP

GlobeNewswire

6 months ago

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
SXTP

GlobeNewswire

7 months ago

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
SXTP

GlobeNewswire

7 months ago

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis

SXTP

Business Wire

7 months ago

Net Asset Value(s)

MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence
SXTP

Business Wire

7 months ago

MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence

RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon
SXTP

Newsfile

7 months ago

RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon

Global Automotive HMI Market Size To Worth USD 75.3 Billion By 2033 l CAGR 12.36%
SXTP

GlobeNewswire

7 months ago

Global Automotive HMI Market Size To Worth USD 75.3 Billion By 2033 l CAGR 12.36%

Entrust Enables Governments to Transform Citizen Interactions with Digital Identities
SXTP

Business Wire

7 months ago

Entrust Enables Governments to Transform Citizen Interactions with Digital Identities

Huawei Reveals How to Reach Premium Asian Tourists at Digital Tourist 2024
SXTP

PR Newswire

7 months ago

Huawei Reveals How to Reach Premium Asian Tourists at Digital Tourist 2024

Dstny honored with 'Employee Wellbeing Award'
SXTP

PR Newswire

7 months ago

Dstny honored with 'Employee Wellbeing Award'

Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
SXTP

GlobeNewswire

7 months ago

Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval

With 58% ownership, Berliner Effektengesellschaft AG (FRA:BFV) insiders have a lot at stake
SXTP

Simply Wall St.

7 months ago

With 58% ownership, Berliner Effektengesellschaft AG (FRA:BFV) insiders have a lot at stake

Better AI Stock: Palantir vs. Snowflake
SXTP

Motley Fool

7 months ago

Better AI Stock: Palantir vs. Snowflake

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?
SXTP

Motley Fool

7 months ago

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

Why We Like The Returns At CTS Eventim KGaA (ETR:EVD)
SXTP

Simply Wall St.

7 months ago

Why We Like The Returns At CTS Eventim KGaA (ETR:EVD)

BigBear.ai Stock: Buy, Sell, or Hold?
SXTP

Motley Fool

7 months ago

BigBear.ai Stock: Buy, Sell, or Hold?

Indonesia's first Olympic gymnast encourages others to 'dream higher'
SXTP

AFP

7 months ago

Indonesia's first Olympic gymnast encourages others to 'dream higher'

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
SXTP

GlobeNewswire

8 months ago

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
SXTP

GlobeNewswire

8 months ago

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results
SXTP

GlobeNewswire

8 months ago

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases
SXTP

GlobeNewswire

8 months ago

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
SXTP

GlobeNewswire

9 months ago

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
SXTP

GlobeNewswire

10 months ago

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

60 Degrees Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
SXTP

Simply Wall St.

10 months ago

60 Degrees Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
SXTP

GlobeNewswire

10 months ago

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
SXTP

GlobeNewswire

a year ago

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
SXTP

GlobeNewswire

a year ago

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

SXTP

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 02/05/2024

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
SXTP

PR Newswire

a year ago

WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
SXTP

GlobeNewswire

a year ago

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
SXTP

PR Newswire

a year ago

WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
SXTP

GlobeNewswire

a year ago

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
SXTP

GlobeNewswire

a year ago

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

SXTP

GlobeNewswire

a year ago

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

Banzai Executes LOI to Acquire Cliently, An AI-Driven Sales Engagement Platform
SXTP

GlobeNewswire

a year ago

Banzai Executes LOI to Acquire Cliently, An AI-Driven Sales Engagement Platform

60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements
SXTP

GlobeNewswire

a year ago

60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements

STRATA Skin Sciences, Inc. (NASDAQ:SSKN): Are Analysts Optimistic?
SXTP

Simply Wall St.

a year ago

STRATA Skin Sciences, Inc. (NASDAQ:SSKN): Are Analysts Optimistic?

Trinity Place Holdings Inc. Enters Into Recapitalization Transactions
SXTP

Business Wire

a year ago

Trinity Place Holdings Inc. Enters Into Recapitalization Transactions

U.S. Energy Corp. Announces Completion of Asset Divestitures and Provides Liquidity Update
SXTP

GlobeNewswire

a year ago

U.S. Energy Corp. Announces Completion of Asset Divestitures and Provides Liquidity Update

Banzai Unveils 2024 Webinar Insights Guide: The Must-Have Resource for Marketers Seeking Successful Webinar Strategies
SXTP

GlobeNewswire

a year ago

Banzai Unveils 2024 Webinar Insights Guide: The Must-Have Resource for Marketers Seeking Successful Webinar Strategies

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
SXTP

NewMediaWire

a year ago

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

STRATA Skin Sciences to Present Poster Showcasing Safety and Efficacy of TheraClear®X for Acne at Maui Derm 2024 Conference
SXTP

GlobeNewswire

a year ago

STRATA Skin Sciences to Present Poster Showcasing Safety and Efficacy of TheraClear®X for Acne at Maui Derm 2024 Conference

SXTP

ACCESSWIRE

a year ago

iAccess Alpha Tax Loss Recovery Summit 2024 - Buyside Best Ideas January 9th-10th 2024

GSI Technology Receives Award from U.S. Air Force Research Laboratory to Demonstrate High-Data Computation Use Cases Leveraging Its Next-Generation APU
SXTP

GlobeNewswire

a year ago

GSI Technology Receives Award from U.S. Air Force Research Laboratory to Demonstrate High-Data Computation Use Cases Leveraging Its Next-Generation APU

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024
SXTP

GlobeNewswire

a year ago

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

Euro Tech Holdings Company Limited Reports Interim Results For The Six Months Ended June 30, 2023
SXTP

PR Newswire

a year ago

Euro Tech Holdings Company Limited Reports Interim Results For The Six Months Ended June 30, 2023

Complete Solaria Appoints Solar Industry Veteran and Growth Expert Chris Lundell as its New CEO
SXTP

GlobeNewswire

a year ago

Complete Solaria Appoints Solar Industry Veteran and Growth Expert Chris Lundell as its New CEO

10 Best Debt Free Penny Stocks To Buy Now
SXTP

Insider Monkey

a year ago

10 Best Debt Free Penny Stocks To Buy Now

Ondas Holdings’ American Robotics and MassDOT Aeronautics to Start a Pilot Program of the Optimus-1EX: the First FAA-Certified Data Capturing Drone System in the U.S.
SXTP

ACCESSWIRE

a year ago

Ondas Holdings’ American Robotics and MassDOT Aeronautics to Start a Pilot Program of the Optimus-1EX: the First FAA-Certified Data Capturing Drone System in the U.S.

Arbe Wins Self-Driving Industry 2023 Award from Cars of the Future
SXTP

PR Newswire

a year ago

Arbe Wins Self-Driving Industry 2023 Award from Cars of the Future

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript
SXTP

Insider Monkey

a year ago

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2024 Earnings Call Transcript

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease
SXTP

GlobeNewswire

a year ago

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

LifeWallet Announces Third Quarter 2023 Financial Results
SXTP

GlobeNewswire

a year ago

LifeWallet Announces Third Quarter 2023 Financial Results

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript
SXTP

Insider Monkey

a year ago

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript

Share on Social Networks: